Navigation Links
Endocare Reports 2008 First Quarter Financial Results
Date:5/1/2008

7.9 Percent Year-Over-Year Increase in Revenue; Gross Margin Increase

Continues; Net Losses Decline

IRVINE, Calif., May 1 /PRNewswire-FirstCall/ -- Endocare, Inc. (Nasdaq: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, today reported solid growth in revenues, cryoprobe sales and procedures and continued expense reductions in the three months ended March 31, 2008, resulting in a 48.1 percent reduction in net loss compared to the first quarter of 2007.

For the first quarter of 2008, total revenues were $8.1 million, up 7.9 percent from $7.5 million in the first quarter of 2007 and up sequentially 17.8 percent from the $6.9 million in the fourth quarter of 2007. Cryoprobe sales in the 2008 first quarter totaled 12,203, an 8.8 percent increase from the 11,211 sold in the first quarter of 2007. The estimated number of domestic cryoablation procedures performed was 2,568, up from 2,315 in the prior-year period.

Endocare Chairman, CEO and President Craig T. Davenport said, "We were pleased with the solid growth we achieved in the first quarter of 2008 over what was a strong first quarter last year. Our sales force continues to report steady progress in its sales activities with prospective physician customers. We believe this is due in part to the continuing publication of clinical research, media coverage of cryoablation and increased physician attention on focal cryoablation at numerous focal cryoablation conferences held around the United States by prestigious medical institutions during the first quarter." Davenport continued, "The launch of our variable cryoprobe, or V-Probe, technology has been received enthusiastically by existing and prospective physicians due in part to the potentially significant advantages that the V-Probe offers. Providing one probe that can create five different-sized isotherms offers the ability to indi
'/>"/>

SOURCE Endocare, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
2. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
3. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
4. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
5. Alexion Reports First Quarter 2008 Results
6. Masimo Reports First Quarter 2008 Financial Results
7. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
8. Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
9. SuperGen Reports 2008 First Quarter Financial Results
10. Emisphere Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
11. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... PARK, Calif. , April 30, 2015  Asterias ... in the emerging field of regenerative medicine, today announced ... results on Thursday, May 7, 2015 after the close ... a conference call and webcast on Thursday, May 7, ... to discuss the results and recent corporate developments. ...
(Date:4/30/2015)... 30, 2015 Available in select ... http://www.lespausa.com , Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield ... skin while battling the weakening threat of inflammaging, ... is formulated with star ingredient GLYCOSEA, a complex ... a complex of soothing minerals and trace elements. ...
(Date:4/29/2015)... According to a new market research report “Vibration ... Component (Accelerometer, Proximity Probe, & Others), Application (Aerospace ... Others), & Geography - Global Forecast to 2020", ... Million by 2020, at a CAGR of 6.6%. ... figures spread through 205 pages and in-depth TOC ...
(Date:4/29/2015)... EAST RUTHERFORD, N.J. , April 29, 2015 ... 2015 financial results will be released on Friday, May 1, ... The Company will host a conference ... Conference Call When: , Friday, ... Dial-in: , 1-888-468-2440 for U.S.1-719-325-2454 for International ...
Breaking Biology Technology:Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... study of single-agent carfilzomib, a next generation proteasome inhibitor, ... achieved an overall response rate (ORR) (partial response or ... response (DOR) of 8.3 months in patients who entered ...
... show scientists the way to make batches of nanotubes of ... Physical Review Letters unveils an elegant formula by ... the energy of a piece of graphene cut at any ... materials science and of chemistry, said this alone is significant ...
... 6 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... the first 60 patients enrolled in the Phase I/II trial ... reported today in an oral presentation at the 52nd American ... Florida. "Anemia is the most serious symptom associated ...
Cached Biology Technology:Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 2Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 3Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 4Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 5Pure nanotube-type growth edges toward the possible 2Pure nanotube-type growth edges toward the possible 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 2YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 4YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 5YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 6
(Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)... YORK , March 23, 2015   HOYOS ... property management company, today announced that the Company will ... for both enterprise and consumers at Connect:ID on March ... HOYOS Labs will highlight the IEEE Biometric ... TM ; and enterprise access control system. BOPS ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... human chromosome 17 and mouse chromosome 11 offers unique ... mammals, said a Baylor College of Medicine researcher who ... the journal Nature. , The work represents the first ... and annotated, said Dr. James R. Lupski, vice chair ...
... at Uppsala University, Sweden has shown in a new study, ... the spot on a male collared flycatcher's forehead reflects how ... influenza. The white spot is also attractive to female birds ... attempted to explain why individuals of a species differ in ...
... action how the "hot" emotional centers of the brain ... involved in memory tasks. Their functional magnetic resonance imaging ... revealed a "see-saw" effect, in which activation of emotional ... such processing. , The findings of the Duke University ...
Cached Biology News:Mouse to man: The story of chromosomes 2Attractive birds more immune against bird flu 2How 'hot' emotional brain interferes with 'cool' processing 2How 'hot' emotional brain interferes with 'cool' processing 3How 'hot' emotional brain interferes with 'cool' processing 4
Polypropylene test tube racks, used in Thermo Forma's line of Test Tube Rack holders...
...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
Autoclavable, variable volumefitted w./ an anti-drip safety valve; borosilicate glass barrelprotected with transparentpolypropylene sleeve; spring-lock cursor design ensuresfine adjustment for exact ...
Biology Products: